Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Expanded Access Program With Nivolumab to Treat Melanoma (Checkmate 168)

Expanded access is no longer available for this treatment.
Information provided by (Responsible Party):
Bristol-Myers Squibb Identifier:
First received: May 16, 2014
Last updated: September 28, 2016
Last verified: September 2016
The purpose of this program is to provide treatment with nivolumab to subjects with Stage III or Stage IV advanced melanoma.

Condition Intervention
Stage III (Unresectable) or Stage IV Advanced Melanoma
Drug: Nivolumab

Study Type: Expanded Access     What is Expanded Access?
Official Title: Expanded Access Program With Nivolumab for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Systemic Treatment Containing an Anti CTLA-4 Monoclonal Antibody (Checkmate 168: CHECKpoint Pathway for nivoluMAb Clinical Trial Evaluation 168)

Resource links provided by NLM:

Further study details as provided by Bristol-Myers Squibb:

Study Start Date: June 2014
Estimated Study Completion Date: May 2018
Estimated Primary Completion Date: May 2018 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both

For more information regarding BMS clinical trial participation, please visit

Inclusion Criteria:

  • ECOG Performance Status of 0-1
  • Histologically confirmed malignant melanoma
  • Progressed on or after treatment with an anti-CTLA4

Exclusion Criteria:

  • Active brain metastases
  • Life Expectancy <6 weeks
  • Subjects who received prior therapy targeting T-cell costimulation or checkpoint pathways except for Anti CTLA-4 therapy
  • Subjects with autoimmune disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02142218

  Show 79 Study Locations
Sponsors and Collaborators
Bristol-Myers Squibb
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
Responsible Party: Bristol-Myers Squibb Identifier: NCT02142218     History of Changes
Other Study ID Numbers: CA209-168 
Study First Received: May 16, 2014
Last Updated: September 28, 2016
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board
Canada: Institutional Review Board
Canada: Health Canada
Brazil: Ethics Committee
Brazil: Ministry of Health

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Antibodies, Monoclonal
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on October 25, 2016